Kornimate/medical-research-clean huggingface dataset:
the effect of dermatology and teledermatology consultations on length of hospital admission, 30 day readmission rate, and antibiotic use in patients presenting with cellulitis vs pseudocellulitis in an academic inpatient setting

Conditions: Cellulitis

Summary: the effect of teledermatology on length of hospital admission, length of stay, 30 day readmission rate, and antibiotic use in patients presenting with cellulitis vs pseudocellulitis in an academic emergency department setting.


Eligibility criteria:
inclusion criteria: * over 18 * admission for cellulitis-like symptoms, including but not limited to the following: tenderness, redness, swelling, expansive lesion exclusion criteria: * pregnant * prisoner
bone turnover and parenteral nutrition

Conditions: Bone Turnover Rate Disorder

Summary: evaluation of changes in biochemical markers of bone metabolism. fat profile. evaluation of the overall body development. assessment of parenteral nutrition protocols.

osteopenia is very common in premature infants, particularly in preterm infants born at extremely low birth weight this is probably related to inadequate calcium and phosphorus intake, which is considerably less than the accretion of these minerals during the last trimester of pregnancy in addition, severe morbidity during the neonatal period (e.g. bronchopulmonary dysplasia \[bpd\]), chronic drug therapy (e.g. diuretics and systemic steroids), the need for total parenteral nutrition and prolonged immobility increase the risk of bone demineralization. total parenteral nutrition is associated with osteopenia in preterm infants. insufficient calcium and phosphate are likely causes; aluminum contamination is another possible contributing factor as this adversely affects bone formation and mineralization. the dha+ara-supplemented formulas supported normal growth and bone mineralization in premature infants who were born at \<33 wk gestation. smof lipid emulsion has a high density of this fatty acids, while intra lipid does not contain any traces of dha. evidence has shown that long-chain polyunsaturated fatty acids (lcpufa), especially the ω-3 fatty acids such as eicosapentaenoic acid (epa) and docosahexaenoic acid (dha) are beneficial for bone health and turnover.

Eligibility criteria:
inclusion criteria: * gestational age \<32 weeks * birth weight \<1500g (vlbw infants) * in need of parenteral nutrition support exclusion criteria: * \>32 weeks of gestation * chromosomal or other abnormalities * parenteral nutrition \<80% of calorie/fluid needs * primary liver disease

Keywords: preterms parenteral lipid
snap wound care system over skin cancer excision sites and split thickness skin grafts (stsgs)

Conditions: Split Thickness Skin Graft; Skin Cancer Excision Site; Skin Graft

Summary: the purpose of this study is to evaluate the efficacy of the spiracur snap® wound care system for the treatment of skin cancer excision sites and split thickness skin grafts (stsg). the secondary purpose will be to compare the prospective patients to retrospectively treated skin cancer excision sites and stsgs to further evaluate efficacy and safety.


Eligibility criteria:
inclusion criteria: * skin cancer excision site and/or stsg as the source of the wound on any part of the body including head and neck, torso, and extremities. any other type of skin graft will also be eligible for inclusion into the study. * wound \< 16 cm in greatest diameter * subject ≥ 18 years of age * female subjects of child-bearing potential must be willing to take a urine pregnancy test prior to starting study * subject is willing and able to sign informed consent exclusion criteria: * wound-related cellulitis * wound located in an area not amenable to forming an air-tight seal * subject has untreated osteomyelitis * subject is allergic to wound care products * wound has exposed blood vessels not suitable for negative pressure therapy * subject is actively participating in other clinical trials that conflict with current study * subject has fistulas * subject is pregnant
pharmacist management of attention deficit hyperactivity disorder medication refill requests

Conditions: Attention-deficit Hyperactivity

Summary: this cluster randomized trial will compare pharmacist management of secure message requests for refills of attention deficit hyperactivity medications with primary care physician management regarding quality of care, timeliness of service, and parent care experience.

importance. enhancing the management of messages from patients and providing high-quality, consistent care are top priorities for the permanente medical group (tpmg) and kaiser foundation hospitals/health plan (kfh/p). a special extension of the ryan haight act currently enables providers to prescribe controlled substances via telehealth interactions, but expires in december 2024. information about the quality of care provided via telehealth prescribing of controlled substances by pharmacists and primary care physicians would be helpful to inform care delivery within kaiser permanente and beyond. objective. to compare pharmacist management of secure message requests for refills of attention deficit hyperactivity disorder (adhd) medications with primary care physician management regarding quality of care, efficiency of service, and parent satisfaction. design, setting, and participants. this cluster randomized clinical trial will include parents of children in kaiser permanente northern california who request adhd medication refills via secure messages from april 29 to june 28, 2024. of kpnc's 63 facilities eligible for inclusion, we will assign 32 to pharmacist care and 31 to pcp care. intervention. in the intervention group, a regional team of pharmacists will manage adhd medication refill requests made via secure message using a standard protocol. in the comparison group, primary care physicians (pediatricians and family medicine physicians) will manage these visits using a similar protocol. main outcomes and measures. the primary outcome is whether a patient who did not have a weight recorded in the 6 months before the refill request was referred for a primary care follow-up visit. secondary outcomes are the days from the secure message request to the prescription order and medication fill, and parent satisfaction. potential results. we will test the hypotheses that pharmacist care compared with pcp care will have higher quality of care, faster time to prescriptions and fills, and higher patient satisfaction. potential conclusions and relevance. if pharmacist care for adhd medication refill requests has better or similar outcomes compared with pcp care, this will provide evidence supporting continuation of this approach. this study's findings will be useful for kpnc and to inform discussions about renewing the special extension of the ryan haight act that allows this approach.

Eligibility criteria:
inclusion criteria: * parent or caregiver requested an adhd medication refill via a secure message exclusion criteria: * the adhd medication refill request was not straightforward and had to be handled by the primary care provider (and thus not eligible for random assignment to pharmacist care or pcp care)
factors determining the prognosis in nsclc stage iv

Conditions: NSCLC Stage IV

Summary: this study is a cohort study with patients with advanced nsclc. patients will answer questionnaires about symptoms and quality of life and will be submitted to physical and blood tests, and computer tomography. the aim of this study is to estimate prognostic factors predicting survival to 3 months in patients with advanced nsclc.

non-small-cell lung cancer (nsclc) is currently the neoplasm leading in deaths worldwide and in brazil. nsclc has a high incidence, is usually diagnosed in advanced stages and has poor survival rates. the ability to refine the prognosis of a disease has implications at the time of diagnosis and decision about treatment. clinical and laboratory factors are studied to evaluated the prognosis of diseases. palliative prognostic score (pap score), karnofsky performance status scale (kps), palliative prognostic index (ppi) are applied in patients with many types of solid tumors. the charlson score evaluates comorbidities and the attributed risk for presence it. others predictors of prognostic are cachexia, quality of life, inflammatory factors, sarcopenia. there is a need to improve the ability to estimate the prognosis and to identify the factors responsible to low survival rates in patients with nsclc diagnosed at advanced stage, also as a tool for a better treatment selection. this is an observational and prospective study, including patients diagnosed with nsclc and admitted in icesp, staged as iv at admission, with no previous systemic treatment and classified as ecog 2-4. demographic data, presence of a caregiver, anthropometry, mrc dyspnea scale, kps, edmont symptom scale, charlson's comorbidity score, ppi and pap were evaluated in each patient. evaluation of sarcopenia and cachexia with abdominal ct (slice-o-matic, v.5), arm circumference, handgrip strength test and quality of life using eortc score qlq c-30 and qlq-cax-24 were also evaluated. significant prognostic factors will be selected by multivariate analysis in a training set estimated as 217 patients.

Eligibility criteria:
inclusion criteria: * advanced stage iva or ivb nsclc patients histologically diagnosis. * eastern cooperative oncology group performance status 2 - 4 * treatment-naive exclusion criteria: * initiate treatment before initiate * psychiatric illnesses, except depression * pregnant or breastfeeding women * two concomitant neoplasms

Keywords: prognostic factor survival lung cancer
tau imaging in subjects with progressive supranuclear palsy, corticobasal degeneration and healthy volunteers

Conditions: Progressive Supranuclear Palsy; Corticobasal Degeneration

Summary: this study will evaluate flortaucipir for brain imaging of tau in subjects with progressive supranuclear palsy (psp), corticobasal degeneration (cbd) and healthy volunteers.


Eligibility criteria:
inclusion criteria: cognitively healthy volunteers * mini-mental state examination (mmse) ≥ 28 * no history of cognitive decline or parkinsonian motor disorder cbd and psp subjects * able to walk 10 steps with minimal assistance * mmse ≥ 14 and ≤ 30 * subject has a reliable study partner who agrees to accompany subject to visits and spends at least 5 hours per week with the subject psp subjects only * meet national institute of neurological disorders and stroke - society for progressive supranuclear palsy (ninds-spsp) probable or possible psp criteria as modified for the neuroprotection and natural history parkinson plus syndromes (nnipps) clinical trial cbd subjects only * meets 2013 consensus criteria for possible or probable corticobasal degeneration, corticobasal syndrome (cbs) subtype exclusion criteria: all subjects * have evidence of structural abnormalities such as vascular disease, large strokes or severe white matter disease or other mass lesion on screening mri * claustrophobia * current clinically significant cardiovascular disease or clinically significant abnormalities on screening electrocardiogram (e.g. corrected qt interval \>450 msec) * have a history of risk factors for torsades de pointes (e.g. heart failure, hypokalemia, family history of long qt syndrome) * have a current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer * females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception * have received or participated in a trial with investigational medications in the past 30 days * have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session * have a history of neuroleptic use for a prolonged period of time or within the past 6 months psp and cbd subjects * have evidence of amyloid deposition * meet national institute on aging-alzheimer's association criteria for probable alzheimer's disease * have any other neurological condition other than cbs or psp that could account for cognitive or motor deficits * serum or plasma progranulin level less than one standard deviation below the normal subject mean for the laboratory performing the assay * have a high-risk family history suggestive of tar dna binding protein (tdp)-43 pathology or known mutations
single-stage ercp and laparoscopic cholecystectomy for cholecystocholedocholithiasis: which to start with?

Conditions: Choledocholithiasis With Cholecystitis; Biliary Stones

Summary: chronic calculous cholecystitis is associated with common bile duct (cbd) stones in approximately 12% of patients. these patients need both cholecystectomy and cbd clearance of stones. the standard for cholecystectomy is laparoscopic cholecystectomy (lc) and the mostly common treatment used for cbd clearance is endoscopic retrograde cholangiopancreatography (ercp). the two interventions can be combined to be done at the same time under single anesthesia session. studies of single stage ercp+lc showed confirmed the safety and efficacy of the combined technique. however, some surgeons start with the ercp while others start with lc.the aim of this study is to compare the start with ercp followed by lc to the start with lc followed by ercp when the two techniques are combined at the same session for treatment of chronic calculous cholecystitis associated with cbd stones regarding efficacy and safety of the two approaches.


Eligibility criteria:
inclusion criteria: * patients underwent single stage ercp+lc for cholecystocholedocholithiasis exclusion criteria: * contraindications to ercp, or laparoscopic surgery * cholangitis and pancreatitis * previously failed ercp

Keywords: choledocholithiasis ercp laparoscopic cholecystectomy cholecystocholedocholithiasis
personalized approach for promoting physical activity in mayo clinic physicians

Conditions: Weight; Well Being

Summary: the purpose of the study is to determine if providing physicians with a walking workstation, exercise counseling, and accelerometer feedback about activity will increase physician activity.

20 physicians will be given an activity monitoring accelerometer (gruve from muve, inc.) for 2 weeks prior to starting the study (without feedback) and will continue to have their activity monitored for the duration of the study. the accelerometer (monitors movement and accurately estimates physical activity energy expenditure). the physicians will be randomized to 12 weeks with accelerometer monitoring but no feedback or counseling (control) or to 12 weeks of accelerometer monitoring (experimental) with feedback about activity levels and 20 minute weekly counseling sessions on how to increase activity (including walking while working). in the 12 week period where physicians receive feedback and counseling, they will also be provided a walking workstation. the walking workstation (assembled by the investigators) has a computer keyboard, computer monitor and telephone attached to an exercise treadmill. this allows the user to walk at 1 mile per hour while dictating, typing, responding to e-mail, etc. the treadmill can be placed in an examining room if the physician wishes to use it while dictating notes or it can be placed in a separate office. those physicians assigned to monitoring only for the first 12 weeks will then receive monitoring plus feedback, counseling, and walking workstation use for the next 12 weeks. those physicians assigned to feedback, counseling, and walking workstation use for the first 12 weeks will continue to receive accelerometer feedback but will no longer receive counseling or use a walking workstation for the subsequent 12 weeks. ten physicians will complete the above for the first 26 weeks of the study and 10 physicians will complete the above for the last 26 weeks of the study. the time line of the study is as follows: 12 wks experimental → 12 wks control 10 mds (wk 1-26) → 2 wks monitor 12 wks control → 12 wks experimental 12 wks experimental → 12 wks control 10 mds (wk 27-52) → 2 wks monitor 12 wks control → 12 wks experimental in summary, physicians use an accelerometer without feedback while in the control group. in the experimental group physicians receive three interventions: accelerometer with feedback, exercise counseling, and the use of a walking workstation (treadmill desk).

Eligibility criteria:
inclusion criteria: * physicians working in the department of medicine at mayo clinic rochester * age 25 to 70 years * bmi \> 25 * sedentary (exercise for 30 minutes less than 3 times weekly) exclusion criteria: * metastatic cancer * unable to complete a bruce protocol exercise stress test * planning on retiring in the next 6 months * planning on more than 3 weeks of vacation during the 6 month study * women of child-bearing age who are pregnant or planning on becoming pregnant.

Keywords: activity level weight body fat well being
an open-label, multidose dose-escalation study to understand the safety of crispr gene-editing therapy and its long-lasting effects in dmd patients (muscle)

Conditions: Duchenne Muscular Dystrophin (DMD)

Summary: duchenne muscular dystrophin (dmd) is an x-linked, fatal muscle-wasting disease caused by mutations in the dmd gene encoding the dystrophin proteins, with symptom onset before age of 6 years in boys. these mutations abolish dystrophin production in the muscle, leading to dystrophin deficiency at the myofiber membrane, continued fiber degeneration, the need for assisted ventilation, respiratory inflammation, loss of walking ability in their teens, followed by respiratory and cardiac decline, and eventually premature death before the age of 30. currently, there are only glucocorticoids for the standard supportive therapy of dmd, which can improve disease symptoms but do not change the outcome of the disease, three antisense oligonucleotide (asos) medicines have been approved to treat dmd with exon 45-55 hotspot region mutations. however, they can only restore trace amounts of dystrophin protein, which is insufficient to bring real clinical benefits. gene replacement therapy has been approved using adeno-associated virus (aav) vectors to deliver the "mini-dystrophin" gene. yet, mini-dystrophin gene-expression versions of truncated dystrophin functionality are sacrificed and limited. hg302 uses a single aav vector to deliver the crispr/hfcas12max dna editing system in the human dmd exon 51 splice donor site. preclinical studies have shown that a single intravenous injection of hg302 significantly restores dystrophin protein expression in muscle fibers and rescues their muscle function in humanized dmd mice to wild-type levels, with long-lasting and durable efficacy.


Eligibility criteria:
inclusion criteria: * males ≥ 4 and ≤8 years at the time of signing informed consent, with clinical diagnosis of dmd; * dmd gene mutation types are deletions in exons 52, 52-61, or 52-63; * able to walk at least 10 meters independently; * willing to cooperate with muscle biopsy test; * acceptable hematology, clinical chemistry, and urine laboratory parameters. exclusion criteria: * presence of active infection; * presence of dmd-associated cardiomyopathy manifestations; * respiratory insufficiency requiring invasive or non-invasive ventilation; * serious infections such as pneumonia, pyelonephritis, or meningitis within 4 weeks prior to receiving trial drug infusion; * prior central nervous system surgery within 6 months before enrolment; * use of any investigational drug, or exon-skipping drug (whether investigational or not) 6 months prior to screening; * previous treatment with any gene therapy or cell therapy (e.g., stem cell transplantation); * any other conditions that would not allow the potential subject to complete follow-up examinations during the study and would, in the opinion of the investigator, make the potential subject unsuitable for the study.

Keywords: dmd dystrophin gene-editing hg302 crispr
prevention of recurrence and metastasis of colorectal cancer by comparing huaier with capecitabine monotherapy

Conditions: Colorectal Cancer

Summary: this is a prospective, multicenter, randomized, parallel controlled study to evaluate the effectiveness of huaier granule in preventing recurrence and metastasis after radical resection of colorectal cancer

it is expected to include 756 patients with colorectal cancer (crc) who were diagnosed as stage ii and underwent radical resection (r0) according to the csco colorectal cancer guidelines 2022 and met the criteria for cabetabine monotherapy in the study center from july 2024 to june 2026. the experimental group was treated with huaier granule monotherapy, and 378 patients were expected to be included; the control group was treated with capecitabine monotherapy, and 378 cases were expected to be included. patients in the experimental group began using huaier granules within 14 days-2 months after surgery. patients in control group received capecitabine treatment, with one course of treatment every 3 weeks, for a total of 4-6 courses. patients will be visited every 12 weeks (± 14 days) for the first two years after enrollment, and every 24 weeks (± 14 days) for the third year, until the end of the study, withdrawal from the study for any reason, or death, whichever occurs first.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old, regardless of gender. * it is diagnosed as colorectal cancer by histopathology, tnm stage ⅱ. * received radical resection of colorectal cancer (r0) within 12 weeks prior to enrollment. * not receiving neoadjuvant therapy before surgery, and not receiving any adjuvant therapy after surgery. * ecog score 0-2 points. * according to the csco colorectal cancer guidelines 2022, it meets the criteria for receiving monotherapy adjuvant therapy with capecitabine. * clear consciousness, language expression or reading ability, able to communicate normally, and cooperate in completing questionnaire assessments. * voluntarily join this study and sign an informed consent form. exclusion criteria: * low rectal cancer (occurring within 12 centimeters from the anal margin) * combining medical history of other malignant tumors. * known to be allergic to the components of huaier granules or avoid or use huaier granules with caution (only in the experimental group). * inability to take orally medication (experimental group, control group with oral medication included in standard treatment plan). * pregnant or lactating women or planned pregnancy preparation. * in the past one month, the subjects have received huaier granules or traditional chinese patent medicines and simple preparations with similar efficacy or indications to huaier granules (such as compound cantharides capsules, cinobufacin capsules, kangai injection, pingxiao tablets, please refer to the instruction manual for details). * refusal to cooperate with follow-up. * other reasons leading to the researcher's belief that it is not suitable to participate in this study.

Keywords: huaier granule colorectal cancer capecitabine recurrence and metastasis